Michael McCormack, Ph.D.
Professor
Research Interests
The focus of my research is assessment of issues related to quality of life in individuals and families affected with inherited neurodegenerative disorders like Huntington Disease and the impact on pharmacological and psycho-social intervention. Parameters of interest in our research include familial phenotypic variation in age of onset and progression of neuro-degeneration related to genomic mutations. Dr. McCormack is director of the NJ statewide HDSA-Center of Excellence for Huntington Disease at Rowan University and Rutgers University and collaborates with the international Enroll-HD Project and U.S. HD Study Group on clinical trials. He is appointed by the Governor of New Jersey as the Chair of the Governor’s Council for Prevention of Developmental Disabilities based in the NJ Department of Human Services.
Publications
Carlozzi NE, Boileau NR, Roché MW, Ready RE, Perlmutter JS, Chou KL, Barton SK, McCormack MK, Stout JC, Cella D, Miner JA, Paulsen JS. Responsiveness to change over time and test-retest reliability of the PROMIS and Neuro-QoL mental health measures in persons with Huntington disease (HD). Quality of Life Research. 2020 Aug 19. doi: 10.1007/s11136-020-02596-1. PMID: 32813263.
Carlozzi NE, Boileau NR, Hahn EA, Barton SK, Cella D, McCormack MK, Ready RE. Responsiveness to change over time: An examination of the neuro-QoL social function measures in persons with Huntington's disease. Journal of Huntington’s Disease. 2020;9(1):83-97. doi: 10.3233/JHD-190385. PMID: 31744014.
Carlozzi NE, Boileau NR, Paulsen JS, Downing NR, Ready R, Perlmutter JS, Cella D, Chou KL, McCormack MK, Barton S, Lai JS. Psychometric properties and responsiveness of Neuro-QoL Cognitive Function in persons with Huntington disease (HD). Quality of Life Research. 2019 Dec 18. doi: 10.1007/s11136-019-02391-7. PMID: 31853881. PMCID: PMC7195233.
Carlozzi NE, Schilling SG, Boileau NR, Chou KL, Perlmutter JS, Frank S, McCormack MK, Stout JC, Paulsen JS, Lai JS, Dayalu P. How different aspects of motor dysfunction influence day-to-day function in Huntington's disease. Movement Disorders. 2019 Dec;34(12):1910-1914. Epub 2019 Oct 14. doi: 10.1002/mds.27866. PMID: 31609508. PMCID: PMC7025393.
Carlozzi NE, Boileau NR, Chou KL, Ready RE, Cella D, McCormack MK, Miner JA, Dayalu P. HDQLIFE and neuro-QoL physical function measures: Responsiveness in persons with Huntington's disease. Movement Disorders. 2019 Nov 14. doi: 10.1002/mds.27908. PMID: 31724237. PMCID: PMC7041888.
Carlozzi NE, Goodnight S, Kratz AL, Stout JC, McCormack MK, Paulsen JS, Boileau NR, Cella D, Ready RE. Validation of Neuro-QoL and PROMIS mental health patient reported outcome measures in persons with Huntington disease. Journal of Huntington's Disease. 2019 Aug 16. doi: 10.3233/JHD-190364. PMID: 31424415. [Epub ahead of print]
Carlozzi NE, Boileau NR, Paulsen JS, Perlmutter JS, Lai JS, Hahn EA, McCormack MK, Nance MA, Cella D, Barton SK, Downing NR. End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning. Journal of Neurology. 2019 Jun 12. doi: 10.1007/s00415-019-09417-7. PMID: 31190171. PMCID: PMC6766417.
Ready RE, Boileau NR, Barton SK, Lai JS, McCormack MK, Cella D, Fritz NE, Paulsen JS, Carlozzi NE. Positive affect and well-being in Huntington's disease moderates the association between functional impairment and HRQOL outcomes. Journal of Huntington’s Disease. 2019;8(2):221-232. doi: 10.3233/JHD-180341. PMID: 31045519.
Wesson M, Boileau NR, S Perlmutter JS, Paulsen J, Barton SK, McCormack MK, Carlozzi NE. Suicidal ideation assessment in individuals with premanifest and manifest Huntington disease. Journal of Huntington’s Disease. 2018 Jul 27. doi: 10.3233/JHD-180299. PMID: 30056431. PMCID: PMC6108173.
Fritz NE, Boileau NR, Stout JC, Ready R, Perlmutter JS, Paulsen JS, Quaid K, Barton S, McCormack MK, Perlman SL, Carlozzi NE. Relationships among apathy, health-related quality of life, and function in Huntington’s disease. Journal of Neuropsychiatry and Clinical Neurosciences. 2018 Jul;30(3):194-201. doi: 10.1176/appi.neuropsych.17080173. PMID: 29558861. PMCID: PMC6081241.
Carlozzi NE, Boileau NR, Perlmutter JS, Chou KL, Stout JC, Paulsen JS, McCormack MK, Cella D, Nance MA, Lai J-S, Dayalu P. Agreement between clinician-rated versus patient-reported outcomes in Huntington disease. Journal of Neurology. 2018 Jun;265(6):1443-1453. Epub 2018 Apr 23 doi: 10.1007/s00415-018-8852-5. PMID: 29687215. PMCID: PMC5992091.
Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG, HDQLIFE Site Investigators and Coordinators. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. Journal of Neurology. 2018 Jan;265(1):98-107. Epub 2017 Nov 15. doi: 10.1007/s00415-017-8677-7. PMID: 29143208. PMCID: PMC5762414.
Downing NR, Goodnight S, Chae S, Perlmutter JS, McCormack M, Hahn E, Barton SK, Carlozzi N. Factors associated with end-of-life planning in Huntington disease. American Journal of Hospice & Palliative Medicine. 2018 Mar;35(3):440-447. Epub 2017 Jun 28. doi: 10.1177/1049909117708195. PMID: 28655280.
Lai JS, Goodnight S, Downing NR, Ready RE, Paulsen JS, Kratz AL, Stout JC, McCormack MK, Cella D, Ross C, Russell J, Carlozzi NE. Evaluating cognition in individuals with Huntington disease: NeuroQoL cognitive functioning measures. Quality of Life Research. 2018 Mar;27(3):811-822. Epub 2017 Dec 8. doi: 10.1007/s11136-017-1755-6. PMID: 29222609. PMCID: PMC5845825.
Lowrimore P, Mulvihill D, Epstein A, McCormack M, Wang YH. CAG nucleotide repeat profiles in persons with schizophrenia or schizoaffective disorders with and without tardive dyskinesia: Pilot study. American Journal of Medical Genetics Part B-Neuropsychiatric Genetics. Jul 1 2004;128B(1):15-18.
Boileau NR, Stout JC, Paulsen JS, Cella D, McCormack MK, Nance MA, Frank S, Lai JS, Carlozzi NE. Reliability and Validity of the HD-PRO-Triad TM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease. Journal of Huntington’s Disease. 2017;6(3):201-215. doi: 10.3233/JHD-170238. PMID: 2896823
Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG, HDQLIFE Site Investigators and Coordinators. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning
Journal of Neurology. 265:97-108, 2018. 2017 Nov 15. [Epub ahead of print]. doi: 10.1007/s00415-017-8677-7. PMID: 29143208.
Carlozzi NE, Schilling SG, Lai JS, Paulsen JS, Hahn EA, Perlmutter JS,Ross CA, Downing NR, Kratz AL, McCormack MK, Nance MA, Quaid KA, Stout JC, Gershon RC, Ready RE, Miner JA, Barton SK, Perlman SL, Rao SM, Frank S, Shoulson I, Marin H, Geschwind MD, Dayalu P, Goodnight SM, Cella D. HDQLIFE: development and assessment of health-related quality of life in Huntington disease (HD). Quality of Life Research. 2016 Oct;25(10):2441-2455. Epub 2016 Aug 13. doi: 10.1007/s11136-016-1386-3. PMID: 27522213.
Carlozzi NE, Downing NR, McCormack MK, Schilling SG, Perlmutter JS, Hahn EA, Lai J-, Frank S, Quaid KA, Paulsen JS, Cella D, Goodnight SM, Miner JA, Nance MA. New Measures to capture end of life concerns in Huntington disease: Meaning and Purpose and Concern with Death and Dying from HDQLLIFE (a patient-reported outcomes measurement system). Quality of Life Research. 2016 Oct;25(10):2403-2415. Epub 2016 Jul 8. doi: 10.1007/s11136-016-1354-y. PMID: 27393121. PMCID: PMC5011453.
Lai JS, Goodnight S, Downing NR, Ready RE, Paulsen JS, Kratz AL, Stout JC, McCormack MK, Cella D, Ross C, Russell J, Carlozzi NE.Evaluating cognition in individuals with Huntington disease: NeuroQoL cognitive functioning measures. Quality of Life Research. 2017 Dec 8. doi: 10.1007/s11136-017-1755-6. PMID: 29222609.
Carlozzi NE, Hahn EA, Frank SA, Perlmutter JS, Downing ND, McCormack MK, Barton S, Nance MA, Schilling SG, HDQLIFE Site Investigators and Coordinators. A new measure for end of life planning, preparation, and preferences in Huntington disease: HDQLIFE end of life planning. Journal of Neurology. 2018 Jan;265(1):98-107. Epub 2017 Nov 15. doi: 10.1007/s00415-017-8677-7. PMID: 29143208. PMCID: PMC5762414
Hillen ME, Kennedy CA, McCormack M, Hirapara K, Kneisser E, Fadem B, Okeorji C Gender affects factors associated with placement into long-term care of patients with Huntington's disease. [Meeting Abstract 32]. Neurotherapeutics. 2018 Jan;(15)1:248-249. doi: 10.1007/s13311-017-0579-y.